GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Accounts Payable

Contineum Therapeutics (Contineum Therapeutics) Accounts Payable : $0.57 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Accounts Payable?

Contineum Therapeutics's Accounts Payable for the quarter that ended in Mar. 2024 was $0.57 Mil.

Contineum Therapeutics's quarterly Accounts Payable declined from Sep. 2023 ($1.05 Mil) to Dec. 2023 ($0.64 Mil) and declined from Dec. 2023 ($0.64 Mil) to Mar. 2024 ($0.57 Mil).

Contineum Therapeutics's annual Accounts Payable declined from Dec. 2021 ($0.66 Mil) to Dec. 2022 ($0.43 Mil) but then increased from Dec. 2022 ($0.43 Mil) to Dec. 2023 ($0.64 Mil).

Contineum Therapeutics Accounts Payable Historical Data

The historical data trend for Contineum Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Accounts Payable Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Accounts Payable
0.66 0.43 0.64

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Accounts Payable Get a 7-Day Free Trial 0.43 - 1.05 0.64 0.57

Contineum Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Contineum Therapeutics Accounts Payable Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics (Contineum Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Accounts Payable
Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Website
https://www.contineum-tx.com
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus

Contineum Therapeutics Announces Pricing of Initial Public Offering

By GlobeNewswire • 04-05-2024